1. Identification of fibronectin type III domain containing 3B as a potential prognostic and therapeutic target for pancreatic cancer: a preliminary analysis
   Yizhi Wang et al, 2024, European Journal of Medical Research CrossRef
2. 6:2 Cl-PFESA, a proposed safe alternative for PFOS, diminishes the gemcitabine effectiveness in the treatment of pancreatic cancer
   Jiawei Hong et al, 2024, Journal of Hazardous Materials CrossRef
3. Post-translational modifications in drug resistance
   Chenggui Miao et al, 2024, Drug Resistance Updates CrossRef
4. Histone modification and personalized epigenomics in cancer
   Shahin Ramazi et al, 2024, Personalized Epigenetics CrossRef
5. Nicotine promotes epithelial to mesenchymal transition and gemcitabine resistance via hENT1/RRM1 signalling in pancreatic cancer and chemosensitizing effects of Embelin-a naturally occurring benzoquinone
   null Prashanth N et al, 2024, Science of The Total Environment CrossRef
6. YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer
   Borui Li et al, 2024, Cancer Letters CrossRef